AMRX AMNEAL PHARMACEUTICALS INC CLASS A
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about AMNEAL PHARMACEUTICALS INC CLASS A: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8059
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8074
Recent analyst activity · last 90 days
Our tracked history has 12 reports on AMRX from 9 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 5 raised their price target and 2 have their first observed target in the past year.
Ratings, latest available report against the previous one: 1 upgrade and 0 downgrades.
Latest observed target change: SVB Leerink raised its target from $23.00 (set 9 Sep 2026) to $25.00 on 5 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Glen Santangelo | Buy | 17 Sep 2026 | 20.00 USD |
| Goldman Sachs | Matt Dellatorre | Buy | 29 Oct 2026 | 24.00 USD |
| JPMorgan | Chris Schott | Buy | 22 Oct 2026 | 24.00 USD |
| Leerink Partners | Daniel Clark | Buy | 9 Sep 2026 | 23.00 USD |
| Oppenheimer | Les Sulewski | Buy | 23 Sep 2026 | 27.00 USD |
| Piper Sandler | David Amsellem | Buy | 3 Nov 2026 | 21.00 USD |
| UBS | Ashwani Verma | Buy | 1 Oct 2026 | 25.00 USD · 3 Aug 2026 |
| Weiss Ratings | Unnamed analyst | — | 8 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 26 Oct 2026 | 23.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 02:46 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.